Efficacy of T2 Magnetic Resonance Assay in Monitoring Candidemia after Initiation of Antifungal Therapy: the Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) Trial

Eleftherios Mylonakis, Ioannis M Zacharioudakis, Cornelius J Clancy, M Hong Nguyen, Peter G Pappas, Eleftherios Mylonakis, Ioannis M Zacharioudakis, Cornelius J Clancy, M Hong Nguyen, Peter G Pappas

Abstract

The performance of blood culture for monitoring candidemia clearance is hampered by its low sensitivity, especially during antifungal therapy. The T2 magnetic resonance (T2MR) assay combines magnetic resonance with nanotechnology to identify whole Candida species cells. A multicenter clinical trial studied the performance of T2MR in monitoring candidemia clearance compared to blood culture. Adults with a blood culture positive for yeast were enrolled and had blood cultures and T2MR testing performed on prespecified days. Thirty-one patients completed the trial. Thirteen of the 31 patients (41.9%) had at least one positive surveillance T2MR and/or blood culture result. All positive blood cultures (7/7 [100%]) had an accompanying positive T2MR result with concordance in the identified Candida sp., while only 7/23 (30.4%) T2MR results had an accompanying positive blood culture. There was one case of discordance in species identification between T2MR and the preenrollment blood culture with evidence to support deep-seated infection by the Candida spp. detected by the T2MR assay. Based on the log rank test, there was a statistically significant improvement in posttreatment surveillance using the T2MR assay compared to blood culture (P = 0.004). Limitations of the study include the small sample size and lack of outcome data. In conclusion, the T2MR assay significantly outperformed blood cultures for monitoring the clearance of candidemia in patients receiving antifungal therapy and may be useful in determining adequate source control, timing for deescalation, and optimal duration of treatment. However, further studies are needed to determine the viability of Candida species cells detected by the T2MR assay and correlate the results with patient outcomes. (This study is registered at ClinicalTrials.gov under registration number NCT02163889.).

Keywords: T2 Candida; T2MR; candidemia; invasive candidiasis; molecular diagnostics; monitor.

Copyright © 2018 Mylonakis et al.

Figures

FIG 1
FIG 1
Graphic representation of study design.
FIG 2
FIG 2
Flow chart of patients in the study.
FIG 3
FIG 3
Kaplan-Meier diagram for the first week of surveillance. chi2, chi-square test.

References

    1. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK, Emerging Infections Program Healthcare-Associated Infections, Antimicrobial Use Prevalence Survey Team. 2014. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370:1198–1208. doi:10.1056/NEJMoa1306801.
    1. Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. 2012. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis 73:45–48. doi:10.1016/j.diagmicrobio.2012.02.001.
    1. Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. 2014. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev 27:490–526. doi:10.1128/CMR.00091-13.
    1. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. 2012. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 54:1739–1746. doi:10.1093/cid/cis305.
    1. Morrell M, Fraser VJ, Kollef MH. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640–3645. doi:10.1128/AAC.49.9.3640-3645.2005.
    1. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. 2016. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62:e1–e50. doi:10.1093/cid/civ1194.
    1. Clancy CJ, Nguyen MH. 2013. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56:1284–1292. doi:10.1093/cid/cit006.
    1. Neely LA, Audeh M, Phung NA, Min M, Suchocki A, Plourde D, Blanco M, Demas V, Skewis LR, Anagnostou T, Coleman JJ, Wellman P, Mylonakis E, Lowery TJ. 2013. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med 5:182ra154. doi:10.1126/scitranslmed.3005377.
    1. Riedel S, Eisinger SW, Dam L, Stamper PD, Carroll KC. 2011. Comparison of BD Bactec Plus Aerobic/F medium to VersaTREK Redox 1 blood culture medium for detection of Candida spp. in seeded blood culture specimens containing therapeutic levels of antifungal agents. J Clin Microbiol 49:1524–1529. doi:10.1128/JCM.02260-10.
    1. Morrell RM Jr, Wasilauskas BL, Steffee CH. 1996. Performance of fungal blood cultures by using the Isolator collection system: is it cost-effective? J Clin Microbiol 34:3040–3043.
    1. Mess T, Daar ES. 1997. Utility of fungal blood cultures for patients with AIDS. Clin Infect Dis 25:1350–1353. doi:10.1086/516140.
    1. Vetter E, Torgerson C, Feuker A, Hughes J, Harmsen S, Schleck C, Horstmeier C, Roberts G, Cockerill F III. 2001. Comparison of the Bactec MYCO/F Lytic bottle to the isolator tube, Bactec Plus Aerobic F/bottle, and Bactec Anaerobic Lytic/10 bottle and comparison of the Bactec Plus Aerobic F/bottle to the Isolator tube for recovery of bacteria, mycobacteria, and fungi from blood. J Clin Microbiol 39:4380–4386. doi:10.1128/JCM.39.12.4380-4386.2001.
    1. Zervou FN, Zacharioudakis IM, Kurpewski J, Mylonakis E. 2017. T2 magnetic resonance for fungal diagnosis. Methods Mol Biol 1508:305–319. doi:10.1007/978-1-4939-6515-1_18.
    1. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG. 2015. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 60:892–899. doi:10.1093/cid/ciu959.
    1. Clancy CJ, Peter PG, Vazquez J, Judson M, Kontoyiannis DP, Thompson GR, Garey KW, Reboli A, Greenberg R, Apewokin S, Lyons M, Ostrosky-Zeichner L, Wu A, Tobin E, Nguyen MH, Caliendo AM. Detecting Infections Rapidly and Easily for Candidemia Trial-2 (DIRECT2): a prospective, multicenter study of the T2Candida Panel. Clin Infect Dis, in press.
    1. Lai CC, Wang CY, Liu WL, Huang YT, Hsueh PR. 2012. Time to positivity of blood cultures of different Candida species causing fungaemia. J Med Microbiol 61:701–704. doi:10.1099/jmm.0.038166-0.
    1. Huang L, Zhang YY, Sun LY. 2013. Time to positivity of blood culture can predict different Candida species instead of pathogen concentration in candidemia. Eur J Clin Microbiol Infect Dis 32:917–922. doi:10.1007/s10096-013-1826-8.
    1. Pfaller MA, Jones RN, Castanheira M. 2014. Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 20062011. Mycoses 57:602–611. doi:10.1111/myc.12206.
    1. Aguilar-Zapata D, Petraitiene R, Petraitis V. 2015. Echinocandins: the expanding antifungal armamentarium. Clin Infect Dis 61(Suppl 6):S604–S611. doi:10.1093/cid/civ814.
    1. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE. 2004. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391–1402. doi:10.1056/NEJMoa040446.
    1. Shields RK, Nguyen MH, Clancy CJ. 2015. Clinical perspectives on echinocandin resistance among Candida species. Curr Opin Infect Dis 28:514–522. doi:10.1097/QCO.0000000000000215.
    1. Arnold HM, Micek ST, Shorr AF, Zilberberg MD, Labelle AJ, Kothari S, Kollef MH. 2010. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 30:361–368. doi:10.1592/phco.30.4.361.
    1. Guinea J. 2014. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 20(Suppl 6):S5–S10. doi:10.1111/1469-0691.12539.
    1. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG. 2015. Reply to Bauer and Goff. Clin Infect Dis 61:487–488. doi:10.1093/cid/civ357.
    1. Bauer KA, Goff DA. 2015. When diagnostic technology is ahead of the hospital budget: what is antimicrobial stewardship to do? Clin Infect Dis 61:486–487. doi:10.1093/cid/civ355.
    1. Bilir SP, Ferrufino CP, Pfaller MA, Munakata J. 2015. The economic impact of rapid Candida species identification by T2Candida among high-risk patients. Future Microbiol 10:1133–1144. doi:10.2217/fmb.15.29.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa